2019
DOI: 10.3389/fchem.2019.00530
|View full text |Cite
|
Sign up to set email alerts
|

Nitric Oxide (NO)-Releasing Macromolecules: Rational Design and Biomedical Applications

Abstract: Nitric oxide (NO) has been recognized as a ubiquitous gaseous transmitter and the therapeutic potential has nowadays received increasing interest. However, NO cannot be easily directly administered due to its high reactivity in air and high concentration-dependent physiological roles. As such, a plethora of NO donors have been developed that can reversibly store and release NO under specific conditions. To enhance the stability and modulate the NO release profiles, small molecule-based NO donors were covalentl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
51
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 57 publications
(57 citation statements)
references
References 73 publications
3
51
0
Order By: Relevance
“…Similarly, NO donors such as SNAP have seen extensive evaluation in vitro at treatment ranges from 100–400 µM with reports of negligible cytotoxicity against coxsackievirus, HSV 1, SARS, influenza virus, and vesicular stomatitis virus [64 , 70 , 120 , 122 , 149] . However, the current lack of IC50 data for many NO donors presents significant challenges in the clinical translation of NO-based therapies in addition to other overarching issues such as drug solubility, stability, and trafficking in vivo [150 , 151] .…”
Section: Pharmacological Considerations For No-based Antiviral Therapmentioning
confidence: 99%
“…Similarly, NO donors such as SNAP have seen extensive evaluation in vitro at treatment ranges from 100–400 µM with reports of negligible cytotoxicity against coxsackievirus, HSV 1, SARS, influenza virus, and vesicular stomatitis virus [64 , 70 , 120 , 122 , 149] . However, the current lack of IC50 data for many NO donors presents significant challenges in the clinical translation of NO-based therapies in addition to other overarching issues such as drug solubility, stability, and trafficking in vivo [150 , 151] .…”
Section: Pharmacological Considerations For No-based Antiviral Therapmentioning
confidence: 99%
“…Polymer represents an efficient platform for NO loading. Polymeric NO donors formed by covalently conjugation or physically encapsulating small molecular-based NO donors to polymer platforms have proven to have excellent NO storage stability, prolonged NO release and optimized pharmacokinetics [38]. To date, various polymer-based NO releasing materials such as nanoparticles, nanofibers, coatings, and hydrogels have been prepared, which have shown great potential for antibacterial applications.…”
Section: No Releasing Polymeric Materials For Antibacterial Applicmentioning
confidence: 99%
“…Furthermore, NO releasing moieties were incorporated with different scaffolds to be applied in many conditions. Polymeric materials can be easily modified and made into various structures, representing powerful scaffolds for NO loading, which can also enhance the stability of NO donors and modulate the NO release profiles [38]. Many polymeric NO releasing materials have been developed for antibacterial application, which demonstrate more significant antibacterial effects than conventional antimicrobial agents while avoiding resistance [39], especially on bacteria in the form of biofilms.…”
Section: Introductionmentioning
confidence: 99%
“…As such, it is of crucial importance to develop NO-releasing materials capable of delivering NO to specific pathological sites and releasing NO on-demand with a proper concentration. In this regard, much effort has been dedicated to various NO-releasing small molecules and nanovectors, including organic-inorganic hybrid materials, macromolecular assemblies, and so on [ 20 , 21 ]. Recently, with the rapid development of MOFs, the high porosity, large surface area, and easy structural adjustment make them promising candidates for NO delivery [ 22 ].…”
Section: Mofs For the Delivery Of Nitric Oxidementioning
confidence: 99%